109 related articles for article (PubMed ID: 31627704)
1. Overview of Current Findings about the Role of Oestrogen Receptor α in Cancer Cell Signalling Pathways.
Voňka P; Hrstka R
Klin Onkol; 2019; 32(Suppl 3):34-38. PubMed ID: 31627704
[TBL] [Abstract][Full Text] [Related]
2. Influence of oestradiol and tamoxifen on oestrogen receptors-alpha and -beta protein degradation and non-genomic signalling pathways in uterine and breast carcinoma cells.
Horner-Glister E; Maleki-Dizaji M; Guerin CJ; Johnson SM; Styles J; White IN
J Mol Endocrinol; 2005 Dec; 35(3):421-32. PubMed ID: 16326830
[TBL] [Abstract][Full Text] [Related]
3. Cryptotanshinone inhibition of mammalian target of rapamycin pathway is dependent on oestrogen receptor alpha in breast cancer.
Pan Y; Shi J; Ni W; Liu Y; Wang S; Wang X; Wei Z; Wang A; Chen W; Lu Y
J Cell Mol Med; 2017 Sep; 21(9):2129-2139. PubMed ID: 28272775
[TBL] [Abstract][Full Text] [Related]
4. Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
Ribas R; Pancholi S; Rani A; Schuster E; Guest SK; Nikitorowicz-Buniak J; Simigdala N; Thornhill A; Avogadri-Connors F; Cutler RE; Lalani AS; Dowsett M; Johnston SR; Martin LA
Breast Cancer Res; 2018 Jun; 20(1):44. PubMed ID: 29880014
[TBL] [Abstract][Full Text] [Related]
5. Interactions between MAP kinase and oestrogen receptor in human breast cancer.
McGlynn LM; Tovey S; Bartlett JM; Doughty J; Cooke TG; Edwards J
Eur J Cancer; 2013 Apr; 49(6):1176-86. PubMed ID: 23265704
[TBL] [Abstract][Full Text] [Related]
6. A transcriptional repressive role for epithelial-specific ETS factor ELF3 on oestrogen receptor alpha in breast cancer cells.
Gajulapalli VN; Samanthapudi VS; Pulaganti M; Khumukcham SS; Malisetty VL; Guruprasad L; Chitta SK; Manavathi B
Biochem J; 2016 Apr; 473(8):1047-61. PubMed ID: 26920025
[TBL] [Abstract][Full Text] [Related]
7. Development of subtype-selective oestrogen receptor-based therapeutics.
Nilsson S; Koehler KF; Gustafsson JÅ
Nat Rev Drug Discov; 2011 Sep; 10(10):778-92. PubMed ID: 21921919
[TBL] [Abstract][Full Text] [Related]
8. Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation.
Martin LA; Farmer I; Johnston SR; Ali S; Dowsett M
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S75-84. PubMed ID: 16113101
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer oestrogen independence mediated by BCAR1 or BCAR3 genes is transmitted through mechanisms distinct from the oestrogen receptor signalling pathway or the epidermal growth factor receptor signalling pathway.
Dorssers LC; van Agthoven T; Brinkman A; Veldscholte J; Smid M; Dechering KJ
Breast Cancer Res; 2005; 7(1):R82-92. PubMed ID: 15642172
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in peptidomimetics antagonists targeting estrogen receptor α-coactivator interaction in cancer therapy.
Qin W; Xie M; Qin X; Fang Q; Yin F; Li Z
Bioorg Med Chem Lett; 2018 Sep; 28(17):2827-2836. PubMed ID: 30025900
[TBL] [Abstract][Full Text] [Related]
11. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
[TBL] [Abstract][Full Text] [Related]
12. RNF168 facilitates oestrogen receptor ɑ transcription and drives breast cancer proliferation.
Liu Z; Zhang J; Xu J; Yang H; Li X; Hou Y; Zhao Y; Xue M; Wang B; Yu N; Yu S; Niu G; Wu G; Li X; Wang H; Zhu J; Zhuang T
J Cell Mol Med; 2018 Sep; 22(9):4161-4170. PubMed ID: 29974997
[TBL] [Abstract][Full Text] [Related]
13. Oestrogen Non-Genomic Signalling is Activated in Tamoxifen-Resistant Breast Cancer.
Poulard C; Jacquemetton J; Trédan O; Cohen PA; Vendrell J; Ghayad SE; Treilleux I; Marangoni E; Le Romancer M
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31195751
[TBL] [Abstract][Full Text] [Related]
14. Wedelolactone induces growth of breast cancer cells by stimulation of estrogen receptor signalling.
Nehybova T; Smarda J; Daniel L; Brezovsky J; Benes P
J Steroid Biochem Mol Biol; 2015 Aug; 152():76-83. PubMed ID: 25934092
[TBL] [Abstract][Full Text] [Related]
15. Estrogen receptor α roles in breast cancer chemoresistance.
Xu CY; Jiang ZN; Zhou Y; Li JJ; Huang LM
Asian Pac J Cancer Prev; 2013; 14(7):4049-52. PubMed ID: 23991950
[TBL] [Abstract][Full Text] [Related]
16. Oncostatin M suppresses oestrogen receptor-α expression and is associated with poor outcome in human breast cancer.
West NR; Murphy LC; Watson PH
Endocr Relat Cancer; 2012 Apr; 19(2):181-95. PubMed ID: 22267707
[TBL] [Abstract][Full Text] [Related]
17. The GPER1/SPOP axis mediates ubiquitination-dependent degradation of ERα to inhibit the growth of breast cancer induced by oestrogen.
Zhang N; Sun P; Xu Y; Li H; Liu H; Wang L; Cao Y; Zhou K; TinghuaiWang
Cancer Lett; 2021 Feb; 498():54-69. PubMed ID: 33069770
[TBL] [Abstract][Full Text] [Related]
18. The complex nature of oestrogen signalling in breast cancer: enemy or ally?
Lipovka Y; Konhilas JP
Biosci Rep; 2016 Jul; 36(3):. PubMed ID: 27160081
[TBL] [Abstract][Full Text] [Related]
19. Oestrogen-related receptors in breast cancer: control of cellular metabolism and beyond.
Deblois G; Giguère V
Nat Rev Cancer; 2013 Jan; 13(1):27-36. PubMed ID: 23192231
[TBL] [Abstract][Full Text] [Related]
20. Xanthohumol suppresses oestrogen-signalling in breast cancer through the inhibition of BIG3-PHB2 interactions.
Yoshimaru T; Komatsu M; Tashiro E; Imoto M; Osada H; Miyoshi Y; Honda J; Sasa M; Katagiri T
Sci Rep; 2014 Dec; 4():7355. PubMed ID: 25483453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
